Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Phathom Pharmaceuticals (PHAT) Net Cash Flow (2022 - 2025)

Phathom Pharmaceuticals (PHAT) has disclosed Net Cash Flow for 4 consecutive years, with -$5.2 million as the latest value for Q4 2025.

  • Quarterly Net Cash Flow rose 86.14% to -$5.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$167.3 million through Dec 2025, down 98.85% year-over-year, with the annual reading at -$167.3 million for FY2025, 98.85% down from the prior year.
  • Net Cash Flow for Q4 2025 was -$5.2 million at Phathom Pharmaceuticals, up from -$14.4 million in the prior quarter.
  • The five-year high for Net Cash Flow was $167.7 million in Q4 2023, with the low at -$84.9 million in Q1 2025.
  • Average Net Cash Flow over 4 years is -$9.1 million, with a median of -$29.5 million recorded in 2022.
  • Peak annual rise in Net Cash Flow hit 556.3% in 2023, while the deepest fall reached 211.16% in 2023.
  • Over 4 years, Net Cash Flow stood at -$41.5 million in 2022, then soared by 504.61% to $167.7 million in 2023, then plummeted by 122.31% to -$37.4 million in 2024, then surged by 86.14% to -$5.2 million in 2025.
  • According to Business Quant data, Net Cash Flow over the past three periods came in at -$5.2 million, -$14.4 million, and -$62.7 million for Q4 2025, Q3 2025, and Q2 2025 respectively.